HEPAD Pilot Study
Research type
Research Study
Full title
Health Economics of Pre-dementia Alzheimer’s Disease (HEPAD): Pilot Study
IRAS ID
305427
Contact name
Filipa Landeiro
Contact email
Sponsor organisation
University of Oxford / Research Governance, Ethics & Assurance
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
The Health Economics of Pre-dementia Alzheimer’s Disease (HEPAD) study is a prospective, multi-centre, UK longitudinal-cohort study that will recruit from, and follow up, a well-phenotyped population identified in The European Prevention of Alzheimer’s Disease – Longitudinal Cohort Study (EPAD-LCS).
The HEPAD study aims to collect data on resources used, costs incurred and health-related quality of life from participants across the spectrum of probability for developing Alzheimer's disease (AD). This study also aims to explore the impact of pre-dementia AD on close friends and relatives by collecting similar data from study partners, who will be selected by enrolled participants. By gathering this health economics information, we aim to avoid delays in introducing new treatments when they become available, as the information will help us to rapidly assess whether a new medication will be cost-effective.
To best achieve the aforementioned aims, The HEPAD Study has been designed as a two-stage study: the first stage is a small-scale pilot study, designed to test the feasibility of the HEPAD study protocol and assess the suitability and acceptability of the health economics measures; the second stage, subject to proof of feasibility, funding and sponsorship, will include the full cohort of participants available through the EPAD-LCS register. This IRAS form outlines the plans for the pilot study only.
REC name
London - South East Research Ethics Committee
REC reference
22/LO/0092
Date of REC Opinion
24 Mar 2022
REC opinion
Further Information Favourable Opinion